Pulmonary function at school-age in surfactant-treated preterm infants

Pediatr Pulmonol. 1999 Mar;27(3):191-8. doi: 10.1002/(sici)1099-0496(199903)27:3<191::aid-ppul7>3.0.co;2-z.


A follow-up study was conducted in 40 children who had been enrolled in a prospective randomized study of exogenous surfactant therapy for respiratory distress syndrome (RDS) (n = 22; S) or placebo (n = 18; P) to determine long-term pulmonary sequelae of surfactant treatment in premature infants with RDS. At follow-up, mean (SD) age was 6.63 (0.18) and 6.55 (0.23) years for S and P, respectively. Complete lung function tests (LFT) were attempted in all patients. Satisfactory data were obtained in 17/22 surfactant-treated and in 12/18 control children. There was no significant difference between groups for any of the parameters measured. Mean (SD) functional residual capacity (FRC) was 92% (16%) and 90% (21%) predicted, mean (SD) airway resistance (R(aw,exp)) was 122% (25%) and 127% (61%), and mean (SD) forced expiratory volume in 1 s (FEV1) was 104% (12%) and 99% (17%) predicted for S and P. Only maximal expiratory flow at 25% vital capacity (L/s) was significantly below the predicted range in S and P groups, with 74% (23%) and 77% (28%), respectively. To test bronchial hyperreactivity, a simple standardized running test was performed: 4 children in S and 5 in P showed a significant response as defined by clinical airway obstruction or changes in FEV1 and/or R(aw), with no significant difference between groups. Although we found no major abnormalities in lung function and no difference between S and P at early school-age, lack of cooperation during lung function tests makes further follow-up necessary.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Age Factors
  • Body Height
  • Chi-Square Distribution
  • Child
  • Female
  • Follow-Up Studies
  • Humans
  • Infant, Newborn
  • Infant, Premature*
  • Lipids / administration & dosage*
  • Male
  • Patient Compliance
  • Phospholipids*
  • Prognosis
  • Pulmonary Surfactants / administration & dosage*
  • Reference Values
  • Respiratory Distress Syndrome, Newborn / drug therapy*
  • Respiratory Function Tests*


  • Lipids
  • Phospholipids
  • Pulmonary Surfactants
  • SF-RI 1, bovine surfactant preparation